Eva Nordström

Title: The Innovative Contributions of Eva Nordström

Introduction

Eva Nordström is a prominent inventor based in Upplands Väsby, Sweden. She has made significant strides in the field of biotechnology, particularly in the development of antibodies that target specific protein aggregates. Her work has the potential to advance therapeutic approaches for neurodegenerative diseases.

Latest Patents

Eva Nordström holds a patent for her invention titled "α-synuclein protofibril-binding antibodies." This patent is based on the discovery of antibodies that selectively target human α-synuclein aggregates, such as oligomers and protofibrils. One notable antibody, BAN0805, demonstrates a lower tendency to bind to the undesired monomeric α-synuclein target compared to the mouse monoclonal antibody mAb47. This innovation could play a crucial role in developing treatments for conditions like Parkinson's disease.

Career Highlights

Throughout her career, Eva has been associated with Bioarctic AB, a company focused on developing innovative therapies for neurodegenerative diseases. Her expertise in antibody development has positioned her as a key figure in the biotechnology sector. With her dedication to research and innovation, she continues to contribute to advancements in medical science.

Collaborations

Eva collaborates with talented professionals in her field, including Jessica Sigvardson and Patrik Nygren. These partnerships enhance the research and development efforts at Bioarctic AB, fostering an environment of innovation and discovery.

Conclusion

Eva Nordström's contributions to the field of biotechnology, particularly through her patent on α-synuclein protofibril-binding antibodies, highlight her role as an influential inventor. Her work not only advances scientific understanding but also holds promise for future therapeutic applications.